Previous 10 | Next 10 |
- Conference call and webcast at 4:30 pm EDT today - - Luxeptinib Phase 1 a/b studies in AML and B cell malignancies continue dose escalation - - APTO-253 Phase 1 a/b study in AML / MDS advances to sixth (210 mg/m 2 ) dose cohort - - Dr. J...
After announcing a complete response in the first dose cohort of a Phase 1a/b AML study, shares of Aptose Biosciences rallied 66% on March 24th to close over $6. This news is backed up by a preclinical study in which luxeptinib demonstrated 100% complete responses in the two highest d...
SAN DIEGO and TORONTO, April 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended March 31, 2...
SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, Presiden...
Are These The Best Health Care Stocks To Buy Before April 2021? No matter the state of the world, the health care industry will likely continue to work towards improving our quality of life. With this being the case, it would make sense then that investors are turning to health ca...
Aptose offered a clinical update with its fourth quarter earnings report that included no new safety/toxicity concerns for luxeptinib, suggesting prior signals were one-offs unrelated to the drug. A complete response in the AML study, at what should be a borderline therapeutic dose le...
Gainers: Cellect Biotechnology APOP +43%, ProQR Therapeutics (PRQR) +33%, Immutep Limited (IMMP) +29%, F-star Therapeutics (FSTX) +24%, Cancer Genetics CGIX +13%.Losers: Evolus EOLS -24%, Rite Aid RAD -24%, Evofem Biosciences (EVFM) ...
Gainers: Aptose Biosciences (APTO) +80%.Color Star Technology (CSCW) +69%.Hall of Fame Resort & Entertainment (HOFV) +51%.Dolphin Entertainment (DLPN) +42%.Phoenix New Media (FENG) +32%.Funko (FNKO) +27%.Vinco Ventures (BBIG) +26%.Cinedigm (CIDM) +23%.Euroseas (ESEA) +19%.Recon ...
Shares of Aptose Biosciences (NASDAQ: APTO) were skyrocketing 70.6% higher as of 11:39 a.m. EDT on Wednesday. The huge gain came after the company provided a fourth-quarter update following the market close on Tuesday that featured new results from an early-stage clinical study eval...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bioscience outfit Aptose (NASDAQ: APTO ) stock is experiencing a boost this morning, fueled by the company’s newest research updates and earnings report. Source: Shutterstock In a Tuesday afte...
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APTO Stock Symbol:
NASDAQ Market:
Aptose Biosciences Inc. Website:
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...
SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies,...
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in...